Praxis Precision Medicines (PRAX) Equity Ratio (2019 - 2026)

Praxis Precision Medicines' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.97 for Q1 2026.

• In Q1 2026, Equity Ratio rose 5.25% year-over-year to 0.97; the TTM figure through Mar 2026 stood at 0.97 (up 5.25% YoY), while the FY2025 annual figure was 0.94, up 1.54% from the prior year.
• Equity Ratio was 0.97 for Q1 2026 at Praxis Precision Medicines, up from 0.94 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2026 to a low of 0.66 in Q1 2023.
• Historically, Equity Ratio has averaged 0.84 across 5 years, with a median of 0.87 in 2025.
• The sharpest annual moves came in 2022 and 2024: Equity Ratio retreated 22.84% in 2022, then jumped 39.98% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.66 in 2022, then advanced by 19.83% to 0.79 in 2023, then rose by 16.4% to 0.92 in 2024, then gained by 1.54% to 0.94 in 2025, then advanced by 3.13% to 0.97 in 2026.
• The last three Equity Ratio figures came in at 0.97 (Q1 2026), 0.94 (Q4 2025), and 0.87 (Q3 2025), per Business Quant data.